AstraZeneca PLC (AZN)vsSanara Medtech Inc (SMTI)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
SMTI
Sanara Medtech Inc
$22.12
+5.48%
HEALTHCARE · Cap: $197.03M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 56132% more annual revenue ($60.44B vs $107.48M). AZN leads profitability with a 17.2% profit margin vs -31.2%. AZN trades at a lower P/E of 27.5x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SMTI
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+58.4%
Fair Value
$46.72
Current Price
$22.12
$24.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
18.6% revenue growth
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.9% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SMTI
The strongest argument for SMTI centers on Revenue Growth. Revenue growth of 18.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SMTI
The primary concerns for SMTI are EPS Growth, Market Cap, Return on Equity. A P/E of 358.3x leaves little room for execution misses. Debt-to-equity of 6.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while SMTI is a growth play — different risk/reward profiles.
SMTI carries more volatility with a beta of 1.19 — expect wider price swings.
SMTI is growing revenue faster at 18.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.2% margins and 12.5% revenue growth. SMTI offers better value entry with a 58.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sanara Medtech Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Sanara MedTech Inc. develops, markets and distributes skin and wound care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company is headquartered in Fort Worth, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?